I think ECF should still be the gold standard in our part of world esp for an high risk older patient and FLOT for a younger patient ECOG 0-1. Grade 3 toxicity is double with the newerFLOT ,so is the reduced dosage or interruption of treatment. CROSS trial also showed that better response in squamous cell cancers as well as path CR. Not to forget that no amount of chemo/radiation would offset the importance of curative surgery R0 with D2 resection.
It’s not the biology of the disease but the biology of the patients and the experience of the center that accounts for unfavorable outcome in our L& M income regions ie Indian subcontinent.
It is still the biology of the disease combined with a good team regardless of geographical boundaries that can give a honest outcome - whether good or bad we don't know.
I think ECF should still be the gold standard in our part of world esp for an high risk older patient and FLOT for a younger patient ECOG 0-1. Grade 3 toxicity is double with the newerFLOT ,so is the reduced dosage or interruption of treatment. CROSS trial also showed that better response in squamous cell cancers as well as path CR. Not to forget that no amount of chemo/radiation would offset the importance of curative surgery R0 with D2 resection.
Agree completely. We've also not had good success with FLOT.
It’s not the biology of the disease but the biology of the patients and the experience of the center that accounts for unfavorable outcome in our L& M income regions ie Indian subcontinent.
It is still the biology of the disease combined with a good team regardless of geographical boundaries that can give a honest outcome - whether good or bad we don't know.
Radical doses in esophageal cancer beyond 5040 cGy didn't show any benefit except increase in toxicity
Yes.
सर नमस्कार, hindi में बताए जिससे ज्यादा लोग fayda utha सके,धन्यवाद
आपके सुझाव को हम मांय रख कर कुछ वीडियोस हिन्दी में बनाएंगे. धन्यवाद्